Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis by Shobana Anpalakhan, Alessio Signori, Alessio Cortellini, Elena Verzoni, Raffaele Giusti, Giuseppe Aprile, Paola Ermacora, Annamaria Catino, Stefania Pipitone, Marilena Di Napoli, Vieri Scotti, Francesca Mazzoni, Pamela F. Guglielmini, Antonello Veccia, Marco Maruzzo, Giovanni Schinzari, Chiara Casadei, Francesco Grossi, Mimma Rizzo, Vincenzo Montesarchio, Francesco Verderame, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Caterina Accettura, Saverio Cinieri, Carlo Alberto Tondini, Andrea Camerini, Maria Chiara Banzi, Mariella Sorarù, Paolo Andrea Zucali, Francesca Vignani, Serena Ricciardi, Antonio Russo, Agnese Cosenza, Massimo Di Maio, Ugo De Giorgi, Sandro Pignata, Diana Giannarelli, Carmine Pinto, Sebastiano Buti, Giuseppe Fornarini, Sara Elena Rebuzzi, Pasquale Rescigno, Alfredo Addeo, Giuseppe L. Banna, Melissa Bersanelli

Get full text

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial thera... by Parth Malik, Ruma Rani, Raghu Solanki, Vishal Haribhai Patel, Tapan Kumar Mukherjee

“…Of late, immune checkpoint inhibitors (ICIs) against various molecules including programmed cell death-1 (PD-1) and its ligand (PD-L1) have been demonstrated as reliable LC treatment targets. …”
Get full text

Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI by Thomas Vogl, Moritz Wildgruber, Cornelius Faber, Emily Hoffmann, Mirjam Gerwing, Stephan Niland, Rolf Niehoff, Max Masthoff, Christiane Geyer, Lydia Wachsmuth, Enrica Wilken, Carsten Höltke, Walter L Heindel, Verena Hoerr, Regina Schinner, Philipp Berger, Johannes A Eble, Bastian Maus, Anne Helfen

“…Subsequently, in vivo experiments aimed to assess changes within the TME and its specific immune cell composition in syngeneic murine breast cancer models with divergent degrees of malignancy (4T1, 67NR) during tumor progression, clodronate liposome-mediated depletion of macrophages, and immune checkpoint inhibitor (ICI) treatment. …”
Get full text

Evolution of the Management of Brain Metastases: A Bibliometric Analysis by Ikram A. Burney, Aya H. Aal Hamad, Syed F. A. Hashmi, Nisar Ahmad, Nadeem Pervez

“…Second, it has moved to the use of novel agents, such as tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) and third, to the use of molecularly directed therapy such as TKIs, in asymptomatic low volume metastasis, obviating the need for WBRT.…”
Get full text

Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer by Lei Gu, Gang Hu, Juan Xiong, Fei Wen

Get full text

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX by Zhu J, Li G, Zhang Z, Wang Y

“…The case provides a potential reference for pMMR CRC patients treating with immune checkpoint inhibitors (ICIs).Keywords: immunotherapy, sintilimab, advanced colon cancer, pathological complete response, microsatellite stability, case report…”
Get full text

The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors by A. D. Koltakova, A. M. Lila, O. G. Alekseeva, A. A. Fedenko, Y. V. Gridneva, A. S. Olshanskaya

“…Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs therapy with musculoskeletal iAEs were examined. …”
Get full text

Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma by Yin Long, Jue Huang, Jianguo Liao, Dongbo Zhang, Ziqi Huang, Xiaodong He, Lei Zhang

Get full text

Estrogenic Activity of Mycoestrogen (3<i>β</i>,5<i>α</i>,22<i>E</i>)-Ergost-22-en-3-ol via Estrogen Receptor α-Dependent Signaling Pathways in MCF-7 Cells by Dahae Lee, Yuri Ko, Changhyun Pang, Yoon-Joo Ko, You-Kyoung Choi, Ki Hyun Kim, Ki Sung Kang

“…The present study evaluated the estrogen-like effects of <i>A. tabescens</i> using a cell-proliferation assay in an estrogen-receptor-positive breast cancer cell line (MCF-7). We found that the methanol extract of <i>A. tabescens</i> fruiting bodies promoted cell proliferation in MCF-7 cells. …”
Get full text

Estrogenic Activity of 4-Hydroxy-Benzoic Acid from <i>Acer tegmentosum</i> via Estrogen Receptor α-Dependent Signaling Pathways by Quynh Nhu Nguyen, Seoung Rak Lee, Baolo Kim, Joo-Hyun Hong, Yoon Seo Jang, Da Eun Lee, Changhyun Pang, Ki Sung Kang, Ki Hyun Kim

“…We evaluated the estrogen-like effects of <i>A. tegmentosum</i> using an estrogen receptor (ER)-positive breast cancer cell line, namely MCF-7, to identify potential phytoestrogens and found that an aqueous extract of <i>A. tegmentosum</i> promoted cell proliferation in MCF-7 cells. …”
Get full text

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors by Ji‐Yeon Kim, Jaeyun Jung, Kyoung‐Mee Kim, Jeeyun Lee, Young‐Hyuck Im

“…Materials and Methods Patients diagnosed with metastatic carcinoma, including colorectal cancer (CRC), breast cancer (BRCA), gastric cancer (GC), non‐small cell lung cancer (NSCLC), and 20 other cancer types, treated in a palliative setting at Samsung Medical Center between October 2019 and April 2021, were enrolled. …”
Get full text

Intercellular Molecular Crosstalk Networks within Invasive and Immunosuppressive Tumor Microenvironment Subtypes Associated with Clinical Outcomes in Four Cancer Types by Jinfen Wei, Wenqi Yu, Lei Wu, Zixi Chen, Guanda Huang, Meiling Hu, Hongli Du

“…Based on the construction of an intercellular infiltration model and unsupervised clustering analysis, four, three, three, and four subTMEs were revealed in breast, colorectal, esophageal, and pancreatic cancer, respectively. …”
Get full text

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da... by Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, On behalf of the Israel Lung Cancer Group

“…In the real-world setting, no statistically significant differences in long-term outcomes with P vs PCT were observed; a prospective randomized trial addressing the comparative efficacy of P and PCT in different patient subgroups is highly anticipated.List of abbreviations: AE - adverse events; ALK - anaplastic lymphoma kinase gene; ALT - alanine aminotransferase; (a)NSCLC - (advanced) non-small cell lung cancer; AST - aspartate aminotransferase; BRAF - v-Raf murine sarcoma viral oncogene homolog B; BRCA2 - BReast CAncer gene 2; c-Met - tyrosine-protein kinase Met; CTCAE, v. 4.03 - Common Terminology Criteria for Adverse Events, version 4.03; CTLA-4 - cytotoxic T-lymphocyte-associated protein 4; ECOG PS - Eastern Cooperative Oncology Group performance status; EGFR - epidermal growth factor receptor gene; FISH - fluorescent in situ hybridization; HER2 - human epidermal growth factor receptor 2; IC - tumor-infiltrating immune cells; ICI - immune check-point inhibitors; IHC - immunohistochemistry; IQR - interquartile range; irAE - immune related adverse events; ISCORT - Israeli Society for Clinical Oncology and Radiotherapy; KRAS - Kirsten rat sarcoma viral oncogene homolog; (m)TTD -(median) time-to-treatment discontinuation; mo - months; (m)OS - (median) overall survival; (m)PFS - (median) progression-free survival; muts/Mb - mutations per megabase; NA - not specified/not available; NOS - not otherwise specified; NR - not reported/not reached; ORR - objective response rate; P - pembrolizumab; PCR - polymerase chain reaction; PCT - combination of pembrolizumab with platinum-based chemotherapy; PD – progression of disease; PD-1 - programmed cell death-1; PD-L1 - programmed cell death ligand-1; pts - patients; RET - proto-oncogene RET; ROS1 - proto-oncogene tyrosine-protein kinase ROS1; SD - standard deviation; STK11 - serine/threonine kinase 11; TC - tumor cells; TMB - Tumor mutation burden; TPS - tumor proportion score.…”
Get full text